Table 2. Descriptive information of the twenty five included studies.
| Study characteristics | Population characteristics | Intervention characteristics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Author
Year Country |
Age Mean (years) | % Female | TMD Diagnostic | Type of pain | TMD Scale | Intervention (n of cases) |
Control
(n of controls) |
Follow-up (n post-baseline) | Measure of effect (VAS scale) | Measure of effect (MIO scale) | ||
| Batabyal et al. 2023 India |
37,91 | 55 | TMD Symptoms | Arthralgia | Platelet-Rich Plasma (30) | Lidocaíne + Triamcinolone (30) | 2 | -1,42 (-2,00; -0,84) | 1,49 (0,99; 196) | |||
| 1.Yapıcı-Yavuz et al. 2018 Turkey |
86,36 | Non-reducing disc displacement of the TMJ | Arthralgia | RDC/TMD | Arthrocentesis + intra-articular injection of sodium hyaluronate (11) | Arthrocentesis (11) | 4 | -0,19 (-0,73; 0,36) | 0,01 (-0,44; 0,46) | |||
| 2.Yapıcı-Yavuz et al. 2018 Turkey |
86,36 | Non-reducing disc displacement of the TMJ | Arthralgia | RDC/TMD | Arthrocentesis + intra-articular injection of methylprednisolone acetate (11) | Arthrocentesis (11) | 4 | 0,13 (-0,41; 0,68) | -0,11 (-0,57; 0,34) | |||
| 3.Yapıcı-Yavuz et al. 2018 Turkey |
86,36 | Non-reducing disc displacement of the TMJ | Arthralgia | RDC/TMD | Arthrocentesis + intra-articular injection of tenoxicam (11) | Arthrocentesis (11) | 4 | -0,01 (-0,55; 0,53) | -0,23 (-0,68; 0,22) | |||
| 1.Martins et al. 2023 Brasil |
34,55 | 91,6 | Sintomas de DTM, estadios III ou IV de Wilkes | Wilkes classification | Arthroscopy + intra-articular injection of 2 mg dexamethasone (24) | Arthroscopy (12) | 3 | -0,47 (-1,05; 0,11) | 0,43 (-0,06; 0,92) | |||
| 2.Martins et al. 2023 Brasil |
34,55 | 91,6 | TMD Symptoms, III ou IV stages of Wilkes | Wilkes classification | Arthroscopy + intra-articular injection of 4 mg dexamethasone (24) | Arthroscopy (12) | 3 | -0,88 (-1,47; -0,29) | 0,35 (-0,14; 0,84) | |||
| 1.Dalewski et al. 2019 Poland |
30,73 | 80 | Myofascial pain | Myalgia | Interocclusal splint + nimesulide (30) | Interocclusal splint (30) | 1 | 1,02 (0,56; 1,48) | ||||
| 2.Dalewski et al. 2019 Poland |
30,73 | 80 | Myofascial pain | Myalgia | Interocclusal splint + dry needling therapy (30) | Interocclusal splint (30) | 1 | -0,83 (-1,29; -0,38) | ||||
| 1.Tepecik et al. 2024 Turkey |
36,30 | 100 | Disc displacement without reduction | Arthralgia | DC/TMD | Arthrocentesis + intra-articular injection of sodium hyaluronate (29) | Interocclusal splint (30) | 2 | -0,69 (-1,22; -0,16) | 0,11 (-0,33; 0,55) | ||
| 2.Tepecik et al. 2024 Turkey |
36,30 | 100 | Disc displacement without reduction | Arthralgia | DC/TMD | Intra-articular injection of iPRF (29) | Interocclusal splint (30) | 2 | -0,36 (-0,89; 0,17) | -0,12 (-0,55; 0,32) | ||
| Pereira et al. 2021 Brasil |
43,91 | 100 | Muscular TMD | Myalgia | DC/TMD | Ozone therapy (25) | Cyclobenzaprine + nimesulide (23) | 2 | -3,30 (-4,04; -2,55) | 1,34 (0,82; 1,87) | ||
| Tchivileva et al. 2020 USA |
34,05 | 77,5 | Muscular TMD | Myalgia | DC/TMD | Propanolol (100) | Placebo (99) | 1 | -0,74 (-1,03; -0,45) | -0,02 (-0,30; 0,26) | ||
| 1.Bechir et al. 2018 Romania |
50,50 | 56,1 | Muscular TMD | Myalgia | DC/TMD | Low level laser therapy (42) | Fastum gel + Clorzoxazone (40) | 7 | -0,59 (-1,04; -0,13) | 1,04 (0,68; 1,40) | ||
| 2.Bechir et al. 2018 Romania |
50,50 | 56,1 | Muscular TMD | Myalgia | DC/TMD | Low level laser therapy + Fastum gel + Clorzoxazone (41) | Fastum gel + Clorzoxazone (40) | 7 | -0,83 (-1,29; -0,37) | 1,63 (1,26; 1,99) | ||
| Venepally et al. 2018 India |
32,43 | 50 | Myofascial pain | Myalgia | Laskin’s criteria, 1969 | Transcutaneous Electrical Nerve Stimulation (20) | Aceclofenac + Paracetamol + Tizanidine (20) | 4 | -0,83 (-1,37; -0,29) | |||
| Gibaly et al. 2024 Egypt |
31,78 | 62,5 | Temporomandibular joint anterior disc displacement, Wilkes stage II | Artralgia | Wilkes classification | Deep dry needling + Dextrose (20) | Deep dry needling (20) | 4 | -0,36 (-0,90; 0,17) | 0,99 (0,54; 1,44) | ||
| Mosleh et al. 2021 Egypt |
27,15 | 70,83 | Anteriorly non reducing disc displacement, Wilkes stage III | Arthralgia + Myalgia | Wilkes classification | Arthrocentesis plus intra-articular injection of azithromycin (12) | Arthrocentesis + intra-articular injection of methylprednisolone acetate ednisolona (12) | 2 | -0,05 (-0,73; 0,64) | -0,21 (-0,80; 0,38) | ||
| Chandra et al. 2021 India |
30,50 | 40,90 | TMD Symptoms | Arthralgia | Intra-articular injection of PRP (22) | Arthrocentesis (22) | 4 | -0,46 (-0,98; 0,07) | 0,35 (-0,08; 0,78) | |||
| 1.Đorđević et al. 2019 Serbia |
38,30 | 84,10 | TMD Symptoms | Arthralgia | Interocclusal splint (20) | Ibuprofeno (16) | 1 | -0,34 (-1,00; 0,32) | ||||
| 2.Đorđević et al. 2019 Serbia |
38,30 | 84,10 | TMD Symptoms | Arthralgia | Interocclusal splint (20) | Diazepam (8) | 1 | -0,29 (-1,12; 0,53) | ||||
| 1.Bilici et al. 2018 Turkey |
Myofascial pain and Internal Derangement | Arthralgia + Myalgia | RDC/TMD | Interocclusal splint plus intra-articular injection of lidocaine (3 times on alternate days) (12) | Interocclusal splint (29) | 2 | -2,84 (-3,59; -2,10) | |||||
| 2.Bilici et al. 2018 Turkey |
Myofascial pain and Internal Derangement | Arthralgia + Myalgia | RDC/TMD | Interocclusal splint plus intra-articular injection of lidocaine (3 times, once a week) (15) | Interocclusal splint (29) | 2 | 0,35 (-0,27; 0,96) | |||||
| Isacsson et al. 2018 Sweden |
52,00 | 81,50 | TMD Symptoms | Arthralgia | DC/TMD | Arthrocentesis + intra-articular injection of methylprednisolone acetate ednisolona (27) | Saline solution (27) | 1 | -0,25 (-0,78; 0,29) | |||
| Ferreira et al. 2023 Brasil |
39,24 | 96,15 | TMD Symptoms | Arthralgia + Myalgia | DC/TMD | Duloxetine (40) | Placebo (38) | 1 | 0,63 (0,18; 1,09) | |||
| Mosleh et al. 2024 Egypt |
88,33 | TMD Symptoms, II, III ou IV stages of Wilkes | Wilkes classification | Arthrocentesis plus intra-articular injection of MESNA (30) | Arthrocentesis + intra-articular injection of sodium hyaluronate (30) | 4 | -3,62 (-4,23; -3,01) | 1,13 (0,72; 1,55) | ||||
Abbreviations: iPRF – Injectable Platelet-Rich Fibrin; PRP – Platelet-Rich Plasma; RDC/TMD – Research Diagnostic Criteria for Temporomandibular Disorders; DC/TMD – Diagnostic Criteria for Temporomandibular Disorders; MESNA – Pharmacological agent (Active ingredient: synthetic sulfhydryl compound).